Randomized phase 2 trial of ketoconazole and ketoconazole/doxorubicin in androgen independent prostate cancer
- 2 May 2001
- journal article
- review article
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 6 (3) , 111-115
- https://doi.org/10.1016/s1078-1439(00)00123-x
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- PROSTATE SPECIFIC ANTIGEN RESPONSE TO MITOXANTRONE AND PREDNISONE IN PATIENTS WITH REFRACTORY PROSTATE CANCER: PROGNOSTIC FACTORS AND GENERALIZABILITY OF A MULTICENTER TRIAL TO CLINICAL PRACTICEJournal of Urology, 2000
- Ketoconazole Retains Activity in Advanced Prostate Cancer Patients with Progression Despite Flutamide WithdrawalJournal of Urology, 1997
- Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patientsCancer, 1996
- Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinomaCancer, 1995
- Phase II study of ketoconazole combined with weekly doxorubicin in patients with androgen-independent prostate cancer.Journal of Clinical Oncology, 1994
- Ketoconazole Effectively Reverses Multidrug Resistance in Highly Resistant KB CellsJournal of Urology, 1994
- Ketoconazole and liarozole in the treatment of advanced prostatic cancerCancer, 1993
- High Dose Ketoconazole for the Treatment of Hormone Refractory Metastatic Prostate Carcinoma: 16 Cases and Review of the LiteratureJournal of Urology, 1989
- Ketoconazole: A Possible Direct Cytotoxic Effect on Prostate Carcinoma CellsJournal of Urology, 1989